Insider Buying: Enovis (NYSE:ENOV) Insider Purchases 1,000 Shares of Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $20.92 per share, with a total value of $20,920.00. Following the transaction, the insider directly owned 53,640 shares in the company, valued at approximately $1,122,148.80. The trade was a 1.90% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average cost of $23.00 per share, with a total value of $23,000.00.
• On Monday, June 1st, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average cost of $22.22 per share, with a total value of $22,220.00.

Enovis Stock Up 2.8%

Shares of ENOV traded up $0.58 during midday trading on Tuesday, hitting $21.56. The company had a trading volume of 1,076,256 shares, compared to its average volume of 1,004,754. The company’s 50 day moving average price is $23.97 and its 200 day moving average price is $24.44. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38. Enovis Corporation has a 52 week low of $20.55 and a 52 week high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period in the previous year, the business posted $0.81 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts predict that Enovis Corporation will post 3.65 EPS for the current year.

Institutional Trading of Enovis

A number of institutional investors have recently made changes to their positions in the stock. Arax Advisory Partners acquired a new stake in Enovis during the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC raised its holdings in shares of Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Danske Bank A S acquired a new stake in shares of Enovis during the third quarter valued at approximately $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Enovis during the third quarter valued at approximately $80,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ENOV. Wells Fargo & Company decreased their price target on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Evercore reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enovis presently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.